Regentis Biomaterials Ltd. (RGNT) Stock Forecast Oct. 16, 2026

On Oct. 16, 2026, RGNT is rated Neutral: its 90-day Alpha forecast sits in the middle 30% of the 5184 stocks scored that day.

Regentis Biomaterials Ltd. is a small-cap company with a market capitalization of $10M. It ranks number 22 by market capitalization among the 27 Orthopedic, Prosthetic & Surgical Appliances & Supplies issuers in our coverage with a current forecast.

For RGNT, the Spearman rank correlation between our 90-day forecasts and the returns that followed is 69.0%, measured on 104 forecast dates between 2026-02-24 and 2026-07-17 on this stock's own recent history. A rank correlation runs from -100% to +100%: it measures whether higher forecasts were followed by higher returns, and a value near zero or below means the model has shown little skill on this stock. On the 30-day forecasts the same correlation is 50.0%, measured on 147 forecast dates between 2026-02-24 and 2026-09-16. Across our coverage, the out-of-sample test on 4495 stocks from 2025-01-06 to 2026-07-07 produced a positive net return in 82.5% of rebalance periods (factor-neutral book, net of estimated costs). Full backtest report

Expected return relative to the market over the horizon: a positive alpha means the model expects the stock to beat the market, whatever the market does. Ratings: strong buy ≥ +1.8%, buy ≥ +0.2%, sell < -0.9%, strong sell < -1.2% (top 15%, next 20%, middle 30%, next 20%, bottom 15% of the 2026-10-16 signals)

All daily signals →